Novartis International AG - Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
Novartis International AG / Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical ...Articles similaires à Novartis International AG - Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
• Sources :
• Mots clés :
• Participer :
• Suivre l'actualité :
BACK TO TOP
